JP2021505578A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021505578A5 JP2021505578A5 JP2020530585A JP2020530585A JP2021505578A5 JP 2021505578 A5 JP2021505578 A5 JP 2021505578A5 JP 2020530585 A JP2020530585 A JP 2020530585A JP 2020530585 A JP2020530585 A JP 2020530585A JP 2021505578 A5 JP2021505578 A5 JP 2021505578A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound according
- independently
- compound
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 150000001768 cations Chemical class 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 0 *COP([*+])(OP(*)(N(*)C(*)(*)C(O*)=O)=*)=O Chemical compound *COP([*+])(OP(*)(N(*)C(*)(*)C(O*)=O)=*)=O 0.000 description 27
- JTGPFMFVEHGDKC-RVEOCHJUSA-N CC(OC([C@H]1[n]2c(nc(nc3N)F)c3nc2)C11O)=C1O Chemical compound CC(OC([C@H]1[n]2c(nc(nc3N)F)c3nc2)C11O)=C1O JTGPFMFVEHGDKC-RVEOCHJUSA-N 0.000 description 1
- ISRGMGHEBIGSQG-ZCFIWIBFSA-N CC(O[C@H](C1)[n]2c(nc(nc3N)Cl)c3nc2)=C1O Chemical compound CC(O[C@H](C1)[n]2c(nc(nc3N)Cl)c3nc2)=C1O ISRGMGHEBIGSQG-ZCFIWIBFSA-N 0.000 description 1
- PFADMNKPUSCMNL-SPDVFEMOSA-N CC[C@H](C(C1)O)O[C@H]1N(C=C(C(N1)=O)F)C1=O Chemical compound CC[C@H](C(C1)O)O[C@H]1N(C=C(C(N1)=O)F)C1=O PFADMNKPUSCMNL-SPDVFEMOSA-N 0.000 description 1
- LMMOTBVCCYRRBE-JXBXZBNISA-N CC[C@H](C(C1)O)O[C@H]1[n]1c(nc(nc2N)Cl)c2nc1 Chemical compound CC[C@H](C(C1)O)O[C@H]1[n]1c(nc(nc2N)Cl)c2nc1 LMMOTBVCCYRRBE-JXBXZBNISA-N 0.000 description 1
- SJXVLXDULLOMPB-FYXMTTTISA-N CC[C@H](C(C12)O)O[F]1[C@H]2[n]1c2nc(Cl)nc(N)c2nc1 Chemical compound CC[C@H](C(C12)O)O[F]1[C@H]2[n]1c2nc(Cl)nc(N)c2nc1 SJXVLXDULLOMPB-FYXMTTTISA-N 0.000 description 1
- GJPQKIQISJHKEA-ZJXFTUPMSA-N C[C@H](C(C1)O)O[C@H]1N(C=C(C(N1)=O)F)C1=O Chemical compound C[C@H](C(C1)O)O[C@H]1N(C=C(C(N1)=O)F)C1=O GJPQKIQISJHKEA-ZJXFTUPMSA-N 0.000 description 1
- LOQMDCLQQLZUPM-QDCZBHAESA-N C[C@H](C(C1[C@@H]2[n]3c(nc(nc4N)Cl)c4nc3)O)OC12F Chemical compound C[C@H](C(C1[C@@H]2[n]3c(nc(nc4N)Cl)c4nc3)O)OC12F LOQMDCLQQLZUPM-QDCZBHAESA-N 0.000 description 1
- ODUODVIWIGWIBR-QDCZBHAESA-N C[C@H](C(C1[C@@H]2[n]3c(nc(nc4N)F)c4nc3)O)OC12O Chemical compound C[C@H](C(C1[C@@H]2[n]3c(nc(nc4N)F)c4nc3)O)OC12O ODUODVIWIGWIBR-QDCZBHAESA-N 0.000 description 1
- WGYIFCKYIGZKEV-QCZWIRADSA-N C[C@H](C1O)OC([C@H]2N(C=CC(N)=N3)C3=O)C12F Chemical compound C[C@H](C1O)OC([C@H]2N(C=CC(N)=N3)C3=O)C12F WGYIFCKYIGZKEV-QCZWIRADSA-N 0.000 description 1
- ZGHWAIXFECZGJH-RRVQCMCFSA-N Nc1nc(Cl)nc2c1nc[n]2[C@@H](C12)C1O[C@H](COP(O)(OP(N(CCC1)[C@@H]1C(OCc1ccccc1)=O)(Oc1ccccc1)=O)=O)C2O Chemical compound Nc1nc(Cl)nc2c1nc[n]2[C@@H](C12)C1O[C@H](COP(O)(OP(N(CCC1)[C@@H]1C(OCc1ccccc1)=O)(Oc1ccccc1)=O)=O)C2O ZGHWAIXFECZGJH-RRVQCMCFSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1720279.7A GB201720279D0 (en) | 2017-12-05 | 2017-12-05 | Anticancer compounds |
| GB1720279.7 | 2017-12-05 | ||
| PCT/GB2018/053525 WO2019110991A1 (en) | 2017-12-05 | 2018-12-05 | Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021505578A JP2021505578A (ja) | 2021-02-18 |
| JP2021505578A5 true JP2021505578A5 (https=) | 2021-12-23 |
| JP7268819B2 JP7268819B2 (ja) | 2023-05-08 |
Family
ID=60950385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020530585A Active JP7268819B2 (ja) | 2017-12-05 | 2018-12-05 | 抗癌剤化合物としてのヌクレオシドのジホスフェートホスホルアミデートの塩 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11560400B2 (https=) |
| EP (2) | EP3720864B1 (https=) |
| JP (1) | JP7268819B2 (https=) |
| KR (1) | KR20200092980A (https=) |
| CN (1) | CN111527098A (https=) |
| AU (1) | AU2018379713A1 (https=) |
| BR (1) | BR112020011221A2 (https=) |
| CA (1) | CA3082269A1 (https=) |
| CL (1) | CL2020001479A1 (https=) |
| DK (1) | DK3720864T3 (https=) |
| EA (1) | EA202091218A1 (https=) |
| ES (1) | ES2910165T3 (https=) |
| GB (1) | GB201720279D0 (https=) |
| HR (1) | HRP20220451T1 (https=) |
| IL (1) | IL274808B2 (https=) |
| MA (2) | MA51006A (https=) |
| MX (1) | MX2020005850A (https=) |
| PH (1) | PH12020550728A1 (https=) |
| PL (1) | PL3720864T3 (https=) |
| PT (1) | PT3720864T (https=) |
| SG (1) | SG11202004342TA (https=) |
| WO (1) | WO2019110991A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL291927A (en) | 2014-11-28 | 2022-06-01 | NuCana plc | Oligonucleotides containing modified nucleosides |
| JP2020164521A (ja) * | 2019-03-29 | 2020-10-08 | 国立大学法人 長崎大学 | 抗ウィルス薬 |
| CN116768949B (zh) * | 2022-07-12 | 2026-03-03 | 南京工业大学 | 一种基于3’-脱氧腺苷经化学修饰改性的具有抗癌效应的化合物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| GB0505781D0 (en) | 2005-03-21 | 2005-04-27 | Univ Cardiff | Chemical compounds |
| WO2010135520A1 (en) | 2009-05-20 | 2010-11-25 | Chimerix, Inc. | Compounds, compositions and methods for treating viral infection |
| GB201016855D0 (en) | 2010-10-06 | 2010-11-17 | Nucana Biomed Ltd | Chemical compounds |
| HUE029022T2 (en) | 2011-03-01 | 2017-02-28 | Nucana Biomed Ltd | Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer |
| WO2014124430A1 (en) * | 2013-02-11 | 2014-08-14 | Emory University | Nucleotide and nucleoside therapeutic compositions and uses related thereto |
| SI3043803T1 (sl) | 2013-09-11 | 2022-09-30 | Emory University | Nukleotidne in nukleozidne sestave in njihova uporaba |
| CN105646629A (zh) | 2014-11-25 | 2016-06-08 | 广州市恒诺康医药科技有限公司 | L-核苷类化合物及其应用 |
| IL291927A (en) | 2014-11-28 | 2022-06-01 | NuCana plc | Oligonucleotides containing modified nucleosides |
| SG10202013032YA (en) * | 2014-12-15 | 2021-02-25 | Univ Emory | Phosphoramidates for the treatment of hepatitis b virus |
| DK3236972T3 (en) | 2014-12-26 | 2021-10-04 | Univ Emory | Antivirale N4-hydroxycytidin-derivativer |
| WO2017106710A1 (en) | 2015-12-17 | 2017-06-22 | Emory University | Nucleotide and nucleoside therapeutic compositions and uses related thereto |
| US20190085013A1 (en) | 2016-03-07 | 2019-03-21 | Emory University | Nucleotide and nucleoside therapeutic compositions and uses related thereto |
| GB201609602D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Chemical compounds |
| GB201609601D0 (en) | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
-
2017
- 2017-12-05 GB GBGB1720279.7A patent/GB201720279D0/en not_active Ceased
-
2018
- 2018-12-05 MA MA051006A patent/MA51006A/fr unknown
- 2018-12-05 AU AU2018379713A patent/AU2018379713A1/en not_active Abandoned
- 2018-12-05 JP JP2020530585A patent/JP7268819B2/ja active Active
- 2018-12-05 MA MA051007A patent/MA51007A/fr unknown
- 2018-12-05 PL PL18819340T patent/PL3720864T3/pl unknown
- 2018-12-05 EP EP18819340.3A patent/EP3720864B1/en active Active
- 2018-12-05 CA CA3082269A patent/CA3082269A1/en active Pending
- 2018-12-05 CN CN201880078576.6A patent/CN111527098A/zh active Pending
- 2018-12-05 SG SG11202004342TA patent/SG11202004342TA/en unknown
- 2018-12-05 DK DK18819340.3T patent/DK3720864T3/da active
- 2018-12-05 PT PT188193403T patent/PT3720864T/pt unknown
- 2018-12-05 WO PCT/GB2018/053525 patent/WO2019110991A1/en not_active Ceased
- 2018-12-05 EA EA202091218A patent/EA202091218A1/ru unknown
- 2018-12-05 ES ES18819340T patent/ES2910165T3/es active Active
- 2018-12-05 HR HRP20220451TT patent/HRP20220451T1/hr unknown
- 2018-12-05 MX MX2020005850A patent/MX2020005850A/es unknown
- 2018-12-05 US US16/769,635 patent/US11560400B2/en active Active
- 2018-12-05 BR BR112020011221-6A patent/BR112020011221A2/pt not_active IP Right Cessation
- 2018-12-05 KR KR1020207016514A patent/KR20200092980A/ko not_active Withdrawn
- 2018-12-05 EP EP21218125.9A patent/EP4043471A1/en not_active Withdrawn
-
2020
- 2020-05-20 IL IL274808A patent/IL274808B2/en unknown
- 2020-05-28 PH PH12020550728A patent/PH12020550728A1/en unknown
- 2020-06-03 CL CL2020001479A patent/CL2020001479A1/es unknown
-
2022
- 2022-12-16 US US18/083,089 patent/US20230192750A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015522650A5 (https=) | ||
| EP4328229A3 (en) | Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof | |
| JP2014500870A5 (https=) | ||
| JP2019518766A5 (https=) | ||
| JP2010511721A5 (https=) | ||
| JP2008510770A5 (https=) | ||
| JP2017526677A5 (https=) | ||
| JP2012515776A5 (https=) | ||
| JP2016506962A5 (https=) | ||
| JP2017509586A5 (https=) | ||
| JP2020517616A5 (https=) | ||
| JP2019513778A5 (https=) | ||
| JP2013544846A5 (https=) | ||
| CN109715626A (zh) | 作为fgfr抑制剂的杂环化合物 | |
| JP2017517538A5 (https=) | ||
| JP2018533593A5 (https=) | ||
| JP2016506958A5 (https=) | ||
| JP2008510828A5 (https=) | ||
| JP2017535614A5 (https=) | ||
| JP2012508252A5 (https=) | ||
| JP2017511321A5 (https=) | ||
| JP2017517565A5 (https=) | ||
| JP2016531126A5 (https=) | ||
| JP2015536997A5 (https=) | ||
| JP2017510660A5 (https=) |